Project Grant R01DE019126

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $204,688 to The Johns Hopkins University to develop a novel immunotherapy approach for treating HPV-associated head and neck cancers. The key products and services to be delivered under this award include: 1) Evaluating the ability of Salmonella-derived nanoparticles coated with the HPV E7 antigen (SOMV-9RE7) to induce...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

This $370,575 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to identify DNA methylation biomarkers for adenoid cystic carcinoma (ACC), a common salivary gland cancer. The key objectives are to: Examine DNA methylation and transcriptomic profiles of 200 clinically annotated ACC tumors to refine subtyping and prognosis. Profile methylation/transcriptome of paired primary and metastatic ACC...

This Cooperative Agreement award, valued at $638,903.00, was granted by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The goal of the project is to validate a novel prognostic biomarker that captures tumor biology and heterogeneity in over 1,000 diverse human papillomavirus positive (HPV+) oropharyngeal cancer (OPC) patients across the United States, Europe, and South America. This research aims to guide...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,062 to The Regents of the University of California, San Francisco to investigate the biological mechanisms contributing to racial disparities in outcomes for head and neck cancer, particularly oral squamous cell carcinoma, in Black patient populations. The research aims to: 1) Develop a prognostic model using gene expression signatures to predict disease progression risk in...

This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...

This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...

The U.S. National Cancer Institute (NCI) awarded a $2,447,812 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The University of Texas M.D. Anderson Cancer Center to conduct research on optimizing oropharyngeal cancer (OPC) survivorship. The 5-year project aims to maintain and enrich the M.D. Anderson OPC Cohort, a prospective longitudinal cancer registry, to support three integrated research projects focused on: 1) osteoradionecrosis, 2) cranial...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 project grant (CFDA No. 93.121 - Oral Diseases and Disorders Research) to Temple University to investigate the role of amplified protein kinases in head and neck squamous cell carcinoma (HNSCC) progression and therapy resistance. The 2-year project aims to test whether the protein kinase TNIK, which is amplified in 20% of HNSCC cases, sustains HNSCC cell proliferation and viability by activating focal...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $229,440 to the University of Colorado-Denver to investigate the divergent response to radio-immunotherapy in head and neck squamous cell carcinoma (HNSCC) and pancreatic adenocarcinoma (PDAC). The research aims to determine how regulatory T cells mediate the different responses observed between these two cancer types...